Does oral semaglutide reduce major adverse cardiovascular events in high-risk type 2 diabetes patients?

In people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo.

Randomized trial · NEJM 2025

Reference: McGuire DK, Marx N, Mulvagh SL. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025; PMID:40162642.

Chapters

0:00 Intro

0:38 The trial

3:07 My take

3:49 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en